載入中
NASDAQHealthcareBiotechnology
最新資料
US$12.24
−US$0.26 · -2.08%
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
一般交易時段
US$12.24
−US$0.26 · -2.08%
盤中時間採用ET。市場資料可能有所延遲。
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
日內區間
目前US$12.24
52週區間
目前US$12.24
盤中時間採用ET。市場資料可能有所延遲。
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
日內區間
目前US$12.24
52週區間
目前US$12.24
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6532.4萬 USD | 6763.5萬 USD | 7920.4萬 USD | 8616萬 USD | 9707.4萬 USD |
| 銷貨成本 | 458.6萬 USD | — | — | — | — |
| 毛利 | 6073.8萬 USD | 6763.5萬 USD | 7920.4萬 USD | 8616萬 USD | 9707.4萬 USD |
| 研究與開發 | 1.07億 USD | 1.31億 USD | 1.64億 USD | 1.65億 USD | 1.74億 USD |
| 銷售、一般及管理費用 | 4393.3萬 USD | 5785萬 USD | 5288.7萬 USD | 4548.2萬 USD | 3253.6萬 USD |
| 營業費用 | 1.46億 USD | 1.89億 USD | 2.16億 USD | 2.1億 USD | 2.07億 USD |
| 利息收入 | 948.1萬 USD | 1477萬 USD | 1136萬 USD | 157.3萬 USD | 202.1萬 USD |
| 利息支出 | 768.1萬 USD | 1094萬 USD | 514.8萬 USD | — | — |
| 折舊和攤銷 | 508.9萬 USD | 233.6萬 USD | 237.1萬 USD | 297.3萬 USD | 333.4萬 USD |
| 營業利益 | −8534.9萬 USD | −1.22億 USD | −1.37億 USD | −1.24億 USD | −1.1億 USD |
| 淨利 | −8188.9萬 USD | −1.16億 USD | −1.34億 USD | −1.22億 USD | −7899.6萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1169.2萬0.00%2.3兆 USD0.03%US$381.71-0.06%
iShares Russell 2000 ETFIWM932.34萬0.01%787.4億 USD0.19%US$278.49-0.16%
Vanguard Extended Market ETFVXF417.95萬0.00%954億 USD0.05%US$234.31-0.29%
iShares Biotechnology ETFIBB267.6萬0.02%108.2億 USD0.44%US$204.81-0.81%
Vanguard Russell 2000 ETFVTWO217.51萬0.01%180億 USD0.06%US$112.49-0.16%
Schwab U.S. Small-Cap ETFSCHA164.42萬0.01%218.24億 USD0.03%US$32.755-0.11%
iShares Russell 2000 Growth ETFIWO161.32萬0.01%139.17億 USD0.24%US$354.44-0.66%
Dimensional - US Small Cap ETFDFAS158.33萬0.00%338.69億 USD0.31%US$78.40+0.06%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
